FDA 483 - Immunity Bio, Inc - February 10, 2023

Immunity Bio, Inc. in Culver City, CA, received a Form 483 observation regarding deficiencies in clinical trial oversight. The firm failed to ensure proper monitoring of study QUILT-3.032, specifically concerning missing monitoring visit reports and undocumented site monitoring visits for several sites. This indicates issues with the management and documentation of clinical trial activities.